Simple Summary Pain associated with cancer diagnoses is a serious concern and one of
the most common symptoms reported by cancer patients. The insufficient relief of cancer …

Worldwide nanotechnology development and application have fueled many scientific
advances, but technophilic expectations and technophobic demands must be …

The growing availability of more effective therapies has contributed to an increased survival
of patients with breast cancer. In hormone receptor-positive early disease, increased …

Estrogen Receptor–Positive Breast Cancer ER-positive, HER2-negative breast cancer,
which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy …

Background The increased number of cancer survivors and the recognition of physical and
psychosocial challenges, present from cancer diagnosis through active treatment and …

Background The MINDACT trial showed excellent 5-year distant metastasis-free survival of
94· 7%(95% CI 92· 5–96· 2) in patients with breast cancer of high clinical and low genomic …

Breast cancer has historically been a disease for which immunotherapy was largely
unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with …

Although 1% is the recommended cut-off to define estrogen receptor (ER) positivity, a 10%
cut-off is often used in clinical practice for therapeutic purposes. We here evaluate clinical …

PURPOSE We aimed to characterize long-term quality of life (QOL) trajectories among
patients with breast cancer treated with adjuvant chemotherapy and to identify related …

PURPOSE Nonadherence to long-term treatments is often under-recognized by physicians
and there is no gold standard for its assessment. In breast cancer, nonadherence to …